Clinical Programs

Equilibra Bioscience obtained exclusive technology licenses of anti-APC mAb from Oklahoma Medical Research Foundation (OMRF).

SR604 is an affinity matured and humanized anti-activated protein C (APC) monoclonal antibody, selectively blocks FVa/FVIIIa degradation by inhibition of APC anticoagulant function, promote hemostatic balance toward clots formation in the surface of vasculature. While SR604 and its parent antibody HAPC1573 preserve APC normal cytoprotective function including endothelial cell barrier protection, and anti-inflammatory effects.